By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Atossa Genetics, Inc. 

4105 East Madison Street
Suite 320
Seattle  Washington  98112  U.S.A.
Phone: 206-325-6086 Fax: 206-325-6087


Company News
Atossa Genetics (ATOS) Completes Enrollment In Endoxifen Phase I Study And Provides Update On Fulvestrant Microcatheter Phase II Study 7/25/2017 11:22:43 AM
Atossa Genetics (ATOS) Announces Warrant Exercises 7/5/2017 12:37:39 PM
Atossa Genetics (ATOS) Receives Positive Safety Committee Assessment Of First Cohort Receiving Oral Formulation Of Endoxifen In Phase I Dose Escalation Study 6/27/2017 7:43:22 AM
Atossa Genetics (ATOS) Completes Enrollment In Topical Arm Of Endoxifen Phase I Study 5/25/2017 6:21:23 AM
Atossa Genetics (ATOS) Announces First Quarter 2017 Financial Results And Provides Company Update 5/16/2017 5:57:29 AM
Atossa Genetics (ATOS) Receives Approval From Institutional Review Board For Continuation Of Its Fulvestrant Microcatheter Phase 2 Study 5/10/2017 1:08:34 PM
Atossa Genetics (ATOS) Receives Positive Interim Review From Independent Safety Committee In Phase I Endoxifen Dose Escalation Study 4/21/2017 12:59:38 PM
Atossa Genetics (ATOS) Enrolls First Cohort Of Eight Subjects In Endoxifen Study 4/4/2017 10:49:55 AM
Atossa Genetics (ATOS) Closes Public Offering 4/3/2017 2:34:39 PM
Atossa Genetics (ATOS) Prices $4,000,000 Public Offering 3/30/2017 1:23:15 PM